In March 2025, the company announced new designs to get a direct-to-buyer offering of its Wegovy weight loss drug. The company proven a whole new pharmacy, known as NovoCare, which would demand consumers $499 per month for use of the drug, fewer than 50 % the cost of the drug by other pharmaceutical distribution networks.[fifty three]Notable for it